Overview
Design and analysis of clinical trials, statistical analysis of biomarker and high dimensional data, development and validation of prognostic and predictive models.
Current Appointments & Affiliations
James B. Duke Distinguished Professor of Biostatistics & Bioinformatics
·
2023 - Present
Biostatistics & Bioinformatics, Division of Biostatistics,
Biostatistics & Bioinformatics
Professor of Biostatistics & Bioinformatics
·
2012 - Present
Biostatistics & Bioinformatics, Division of Biostatistics,
Biostatistics & Bioinformatics
Chief, Division of Biostatistics
·
2019 - Present
Biostatistics & Bioinformatics,
Basic Science Departments
Member of the Duke Cancer Institute
·
1996 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Cytoplasmic versus nuclear localization of androgen receptor splice variant 7 as a predictor of benefit from androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer (PROPHECY trial).
Journal Article Prostate Cancer Prostatic Dis · April 2, 2026 BACKGROUND: Androgen receptor splice variant-7 (AR-V7), a constitutively active truncated protein, is linked to hormone therapy resistance. Nuclear AR-V7 in CTCs correlates with poor response and shorter progression-free survival (PFS) and overall survival ... Full text Link to item CitePathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate Cancer.
Journal Article Eur Urol · April 2026 BACKGROUND AND OBJECTIVE: Although validated prognostic models exist for men with metastatic castration-resistant prostate cancer (mCRPC), current tools do not incorporate genomic biomarkers such as circulating tumor DNA (ctDNA) aneuploidy or pathogenic ge ... Full text Link to item CiteESMO basic requirements for AI-based biomarkers in oncology (EBAI).
Journal Article Ann Oncol · March 2026 BACKGROUND: Artificial intelligence (AI) is expected to introduce an increasing number of biomarkers in oncology. To bridge the gap between oncology and computer science, it is timely to define recommendations for AI-based biomarkers suitable for routine c ... Full text Link to item CiteRecent Grants
The COVID-19 and Cancer Consortium (CCC19) Registry
ResearchPrincipal Investigator · Awarded by Rhode Island Hospital · 2024 - 2029Assessing Prognoses and Validating Surrogate Endpoints for Clinical Outcomes in Metastatic Hormone Sensitive Prostate Cancer
ResearchPrincipal Investigator · Awarded by Department of Defense · 2025 - 2028Research Triangle Center of Excellence in Regulatory Science and Innovation
ResearchPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2023 - 2028View All Grants
Education
University of Texas Health Sciences Center, Houston ·
1994
Ph.D.